がん治療におけるクローデイン-4の標的化

Abstract

The overexpression of claudin-4 (CLDN4) in many cancers has drawn attention to this protein as a new molecular target. There have been a number of attempts to target CLDN4 for cancer therapy. Targeting of CLDN4 is expected to provide multi-layered effects by enabling direct attacks on CLDN4-overexpressing cancer cells, disrupting the intratumoral microenvironment, and facilitating drug delivery by impairing tight junctions. This article describes anti-CLDN4 antibodies, CLDN4 gene knockdown, CPE and C-CPE, and CLDN4 binding peptides and their potential for cancer therapy.